

Jerome de Seze

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5840243/jerome-de-seze-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

274
papers

18,570
citations

62
h-index

130
g-index

323
ext. papers

22,048
ext. citations

5.8
avg, IF

6.18
L-index

#	Paper	IF	Citations
274	International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. <i>Neurology</i> , 2015 , 85, 177-89	6.5	2255
273	A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. <i>New England Journal of Medicine</i> , 2010 , 362, 387-401	59.2	1971
272	Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. <i>New England Journal of Medicine</i> , 2012 , 367, 1087-97	59.2	943
271	Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. <i>Lancet, The</i> , 2012 , 380, 1829-39	40	827
270	MRI characteristics of neuromyelitis optica spectrum disorder: an international update. <i>Neurology</i> , 2015 , 84, 1165-73	6.5	404
269	Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. <i>Medicine (United States)</i> , 2004 , 83, 280-291	1.8	401
268	Neuromyelitis optica and non organ-specific autoimmunity. <i>Archives of Neurology</i> , 2008 , 65, 78-83		387
267	Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the gene encoding the giant skeletal-muscle protein titin. <i>American Journal of Human Genetics</i> , 2002 , 71, 492-500	11	338
266	Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2016 , 387, 1075-1084	40	271
265	Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study. <i>Neurology</i> , 2018 , 90, e1858-e1869	6.5	268
264	Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. <i>JAMA Neurology</i> , 2020 , 77, 1079-1088	17.2	235
263	Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. <i>New England Journal of Medicine</i> , 2019 , 381, 2114-2124	59.2	212
262	MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1719-1731	5	201
261	Radiologically isolated syndrome: 5-year risk for an initial clinical event. <i>PLoS ONE</i> , 2014 , 9, e90509	3.7	190
260	Treatment of Neuromyelitis Optica: Review and Recommendations. <i>Multiple Sclerosis and Related Disorders</i> , 2012 , 1, 180-187	4	176
259	Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 678-88	5	172
258	Neuromyelitis optica in France: a multicenter study of 125 patients. <i>Neurology</i> , 2010 , 74, 736-42	6.5	171

257	Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. <i>Journal of Immunology</i> , 2009 , 183, 4067-76	5.3	161
256	Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 256-9	5	161
255	Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. <i>Neurology</i> , 2011 , 77, 2128-34	6.5	155
254	Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile. <i>Journal of the Neurological Sciences</i> , 2002 , 197, 57-61	3.2	153
253	Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: follow-up of 70 patients. <i>Archives of Neurology</i> , 2009 , 66, 841-6		145
252	Acute myelopathies: Clinical, laboratory and outcome profiles in 79 cases. <i>Brain</i> , 2001 , 124, 1509-21	11.2	142
251	MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. <i>Neurology</i> , 2014 , 82, 1491-8	6.5	141
250	Ofatumumab versus Teriflunomide in Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2020 , 383, 546-557	59.2	132
249	Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. <i>Lancet Neurology</i> , 2012 , 11, 420-8	24.1	128
248	Spastic paraplegia gene 7 in patients with spasticity and/or optic neuropathy. <i>Brain</i> , 2012 , 135, 2980-93	11.2	128
247	Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. <i>Neurology</i> , 2013 , 80, 2194-200	6.5	126
246	Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 1067-73	5	126
245	Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 843-7	5	125
244	Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. <i>Journal of Autoimmunity</i> , 2013 , 43, 60-9	15.5	123
243	Idiopathic acute transverse myelitis: application of the recent diagnostic criteria. <i>Neurology</i> , 2005 , 65, 1950-3	6.5	122
242	Relevance of the antibody index to diagnose Lyme neuroborreliosis among seropositive patients. <i>Neurology</i> , 2007 , 69, 953-8	6.5	117
241	Acute fulminant demyelinating disease: a descriptive study of 60 patients. <i>Archives of Neurology</i> , 2007 , 64, 1426-32		117
240	Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. <i>Journal of Neuroinflammation</i> , 2015 , 12, 46	10.1	112

239	Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013 , 84, 922-30	5.5	112
238	Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study. <i>JAMA Neurology</i> , 2014 , 71, 436-41	17.2	110
237	Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 132-136	5.5	108
236	Is Devic [®] neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2003 , 9, 521-5	5	103
235	Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. <i>Cytokine</i> , 2009 , 45, 55-7	4	102
234	NMO-IgG and Devic [®] neuromyelitis optica: a French experience. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 440-5	5	95
233	Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008 , 79, 195-8	5.5	92
232	Cognitive function in radiologically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 919-25	5	90
231	Is neuromyelitis optica associated with human leukocyte antigen?. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 571-9	5	90
230	Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1135-43	5	88
229	Cognitive functions in neuromyelitis optica. <i>Archives of Neurology</i> , 2008 , 65, 84-8		86
228	Natural history of adult-onset eIF2B-related disorders: a multi-centric survey of 16 cases. <i>Brain</i> , 2009 , 132, 2161-9	11.2	85
227	Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. <i>Archives of Neurology</i> , 2012 , 69, 1259-69		83
226	Optical coherence tomography in neuromyelitis optica. <i>Archives of Neurology</i> , 2008 , 65, 920-3		83
225	Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 399-405	5	80
224	Update on biomarkers in neuromyelitis optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015 , 2, e134	9.1	79
223	Long-term outcomes of CLIPPERS (chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids) in a consecutive series of 12 patients. <i>Archives of Neurology</i> , 2012 , 69, 847-55		79
222	Increased risk of multiple sclerosis relapse after in vitro fertilisation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012 , 83, 796-802	5.5	77

221	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology, The</i> , 2019 , 18, 185-197	24.1	74
220	Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004 , 10, 596-7	5	74
219	Suicidal ideation in Huntington disease: the role of comorbidity. <i>Psychiatry Research</i> , 2011 , 188, 372-6	9.9	69
218	White matter atrophy and cognitive dysfunctions in neuromyelitis optica. <i>PLoS ONE</i> , 2012 , 7, e33878	3.7	69
217	Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. <i>Journal of Neuroinflammation</i> , 2019 , 16, 134	10.1	66
216	Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1086-94	5	66
215	Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 1409-12	5.5	65
214	Current and future treatment approaches for neuromyelitis optica. <i>Therapeutic Advances in Neurological Disorders</i> , 2011 , 4, 111-21	6.6	64
213	Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 1344-50	5.5	62
212	Long-term follow-up of a randomized trial on 118 patients with polyarteritis nodosa or microscopic polyangiitis without poor-prognosis factors. <i>Autoimmunity Reviews</i> , 2014 , 13, 197-205	13.6	61
211	Guillain-Barre syndrome, influenzalike illnesses, and influenza vaccination during seasons with and without circulating A/H1N1 viruses. <i>American Journal of Epidemiology</i> , 2011 , 174, 326-35	3.8	61
210	New antigenic candidates in multiple sclerosis: identification by serological proteome analysis. <i>Proteomics</i> , 2004 , 4, 2184-94	4.8	60
209	Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1377-1384	5	59
208	Quality of life in multiple sclerosis: influence of interferon-beta1 a (Avonex) treatment. <i>Multiple Sclerosis Journal</i> , 2002 , 8, 377-81	5	58
207	Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study. <i>Neurology</i> , 2016 , 86, 771-8	6.5	57
206	Acute limbic encephalitis and glutamic acid decarboxylase antibodies: a reality?. <i>Journal of the Neurological Sciences</i> , 2009 , 287, 69-71	3.2	56
205	CSF isoelectrofocusing in a large cohort of MS and other neurological diseases. <i>European Journal of Neurology</i> , 2004 , 11, 525-9	6	56
204	New insights into cell responses involved in experimental autoimmune encephalomyelitis and multiple sclerosis. <i>Immunology Letters</i> , 2005 , 96, 11-26	4.1	56

203	Prospective study of patients presenting with acute partial transverse myelopathy. <i>Journal of Neurology</i> , 2003 , 250, 1447-52	5.5	54
202	Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study. <i>Muscle and Nerve</i> , 2012 , 46, 687-91	3.4	53
201	JC-virus seroconversion in multiple sclerosis patients receiving natalizumab. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 822-9	5	52
200	Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients. <i>Journal of the Neurological Sciences</i> , 2004 , 218, 73-7	3.2	51
199	Multiple sclerosis and depression: influence of interferon beta therapy. <i>Multiple Sclerosis Journal</i> , 2003 , 9, 284-8	5	51
198	Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2010 , 292, 28-35	3.2	50
197	Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. <i>JAMA Neurology</i> , 2015 , 72, 815-22	17.2	49
196	Impact of pregnancy on conversion to clinically isolated syndrome in a radiologically isolated syndrome cohort. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1297-302	5	48
195	Efficacy of rituximab in refractory neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 955-9	5	47
194	Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. <i>Neurology</i> , 2015 , 84, 1145-52	6.5	47
193	Long-term outcome of acute and subacute myelopathies. <i>Journal of Neurology</i> , 2009 , 256, 980-8	5.5	46
192	Air pollution by particulate matter PM may trigger multiple sclerosis relapses. <i>Environmental Research</i> , 2017 , 156, 404-410	7.9	44
191	Magnetic resonance spectroscopy evaluation in patients with neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010 , 81, 409-11	5.5	44
190	A benign form of neuromyelitis optica: does it exist?. <i>Archives of Neurology</i> , 2011 , 68, 918-24		44
189	Characterization of discriminant human brain antigenic targets in neuropsychiatric systemic lupus erythematosus using an immunoproteomic approach. <i>Arthritis and Rheumatism</i> , 2007 , 56, 3420-32		44
188	Association of multiple sclerosis with ILT6 deficiency. <i>Genes and Immunity</i> , 2005 , 6, 445-7	4.4	44
187	Evaluation of health-related quality of life, fatigue and depression in neuromyelitis optica. <i>European Journal of Neurology</i> , 2011 , 18, 836-41	6	43
186	Cancer and multiple sclerosis in the era of disease-modifying treatments. <i>Journal of Neurology</i> , 2011 , 258, 1304-11	5.5	43

185	Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. <i>Neurology</i> , 2017 , 89, 1584-1593	6.5	42
184	OFSEP, a nationwide cohort of people with multiple sclerosis: Consensus minimal MRI protocol. <i>Journal of Neuroradiology</i> , 2015 , 42, 133-40	3.1	42
183	Patient perceptions of multiple sclerosis and its treatment. <i>Patient Preference and Adherence</i> , 2012 , 6, 263-73	2.4	42
182	Adult-onset genetic leukoencephalopathies: a MRI pattern-based approach in a comprehensive study of 154 patients. <i>Brain</i> , 2015 , 138, 284-92	11.2	41
181	Distortion of the self-reactive IgG antibody repertoire in multiple sclerosis as a new diagnostic tool. <i>Journal of Immunology</i> , 2004 , 172, 669-78	5.3	41
180	Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. <i>Journal of Neurology</i> , 2016 , 263, 140-9	5.5	40
179	Relapsing inflammatory optic neuritis: is it neuromyelitis optica?. <i>Neurology</i> , 2008 , 70, 2075-6	6.5	40
178	Autonomic dysfunction in multiple sclerosis: cervical spinal cord atrophy correlates. <i>Journal of Neurology</i> , 2001 , 248, 297-303	5.5	40
177	Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study. <i>PLoS ONE</i> , 2015 , 10, e0132033	3.7	40
176	Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	40
175	White matter volume is decreased in the brain of patients with neuromyelitis optica. <i>European Journal of Neurology</i> , 2013 , 20, 361-7	6	38
174	Relapsing demyelinating disease affecting both the central and peripheral nervous systems. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008 , 79, 1032-9	5.5	38
173	An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica. <i>Therapeutic Advances in Neurological Disorders</i> , 2016 , 9, 180-8	6.6	37
172	Myelin-oligodendrocyte glycoprotein antibody-associated disease. <i>Lancet Neurology, The</i> , 2021 , 20, 762-772	14.1	37
171	Autoimmune hepatitis and multiple sclerosis: a coincidental association?. <i>Multiple Sclerosis Journal</i> , 2005 , 11, 691-3	5	36
170	Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options. <i>Drugs</i> , 2019 , 79, 125-142	12.1	36
169	Immunological profiles determine neurological involvement in Sjögren's syndrome. <i>European Journal of Internal Medicine</i> , 2014 , 25, 177-81	3.9	35
168	Unusual ocular motor findings in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2006 , 243, 91-5	3.2	35

167	Autophagy in neuroinflammatory diseases. <i>Autoimmunity Reviews</i> , 2017 , 16, 856-874	13.6	34
166	Combination of IFN beta-1a (Avonex) and mycophenolate mofetil (Cellcept) in multiple sclerosis. <i>European Journal of Neurology</i> , 2007 , 14, 85-9	6	34
165	Autonomic and respiratory dysfunction in Charcot-Marie-Tooth disease due to Thr124Met mutation in the myelin protein zero gene. <i>Clinical Neurophysiology</i> , 2003 , 114, 1609-14	4.3	34
164	Observatoire Français de la Sclérose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 118-122	5	34
163	Ozone, NO and PM are associated with the occurrence of multiple sclerosis relapses. Evidence from seasonal multi-pollutant analyses. <i>Environmental Research</i> , 2018 , 163, 43-52	7.9	33
162	Tear analysis in clinically isolated syndrome as new multiple sclerosis criterion. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 87-92	5	33
161	Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. <i>Journal of Neurology</i> , 2010 , 257, 207-11	5.5	33
160	IgG reactivity against citrullinated myelin basic protein in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2001 , 117, 149-55	3.5	33
159	Visual evoked potentials study in chronic idiopathic inflammatory demyelinating polyneuropathy. <i>Clinical Neurophysiology</i> , 2000 , 111, 2285-91	4.3	33
158	Pupillary disturbances in multiple sclerosis: correlation with MRI findings. <i>Journal of the Neurological Sciences</i> , 2001 , 188, 37-41	3.2	33
157	Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study. <i>Journal of the Neurological Sciences</i> , 2016 , 363, 69-76	3.2	32
156	Serum analysis by 1H nuclear magnetic resonance spectroscopy: a new tool for distinguishing neuromyelitis optica from multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 558-65	5	32
155	Lyme optic neuritis. <i>Journal of the Neurological Sciences</i> , 2010 , 295, 117-9	3.2	32
154	Long-term follow-up of acute partial transverse myelitis. <i>Archives of Neurology</i> , 2012 , 69, 357-62		31
153	Challenges and opportunities in designing clinical trials for neuromyelitis optica. <i>Neurology</i> , 2015 , 84, 1805-15	6.5	30
152	Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy. <i>Journal of Neurology</i> , 2012 , 259, 2293-8	5.5	30
151	Vocal cord and diaphragm paralysis, as clinical features of a French family with autosomal recessive Charcot-Marie-Tooth disease, associated with a new mutation in the GDAP1 gene. <i>Neuromuscular Disorders</i> , 2004 , 14, 261-4	2.9	30
150	Clinical spectrum and treatment of neuromyelitis optica spectrum disorders: evolution and current status. <i>Brain Pathology</i> , 2013 , 23, 647-60	6	29

149	Diffusion-weighted imaging in noncompressive myelopathies: a 33-patient prospective study. <i>Journal of Neurology</i> , 2010 , 257, 1438-45	5.5	29
148	A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort. <i>European Journal of Neurology</i> , 2014 , 21, 40-8	6	28
147	Prior suggestive symptoms in one-third of patients consulting for a "first" demyelinating event. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 323-5	5.5	28
146	One-year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2005 , 11, 360-3	5	28
145	Induced brain plasticity after a facilitation programme for autobiographical memory in multiple sclerosis: a preliminary study. <i>Multiple Sclerosis International</i> , 2012 , 2012, 820240	1.1	27
144	Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults. <i>Journal of Neurology</i> , 2019 , 266, 806-815	5.5	27
143	POLG1 variations presenting as multiple sclerosis. <i>Archives of Neurology</i> , 2010 , 67, 1140-3		25
142	Silver stained isoelectrophoresis of tears and cerebrospinal fluid in multiple sclerosis. <i>Journal of Neurology</i> , 2001 , 248, 672-5	5.5	25
141	Radiologically isolated syndrome in children: Clinical and radiologic outcomes. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017 , 4, e395	9.1	24
140	Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis. <i>Neurology</i> , 2019 , 93, e635-e646	6.5	24
139	Lyme neuroborreliosis and dementia. <i>Journal of Alzheimer's Disease</i> , 2014 , 41, 1087-93	4.3	24
138	Autobiographical memory in multiple sclerosis patients: assessment and cognitive facilitation. <i>Neuropsychological Rehabilitation</i> , 2013 , 23, 161-81	3.1	24
137	Neuromyelitis optica. <i>Archives of Neurology</i> , 2003 , 60, 1336-8		24
136	Relapsing optic neuritis: a multicentre study of 62 patients. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 848-53	5	23
135	Diffusion tensor imaging of normal-appearing white matter in neuromyelitis optica. <i>Journal of Neuroradiology</i> , 2012 , 39, 295-300	3.1	23
134	Longitudinal follow-up of vision in a neuromyelitis optica cohort. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1320-2	5	23
133	Central nervous system abnormalities in patients with PMP22 gene mutations: a prospective study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013 , 84, 392-7	5.5	23
132	Strategy for anti-aquaporin-4 auto-antibody identification and quantification using a new cell-based assay. <i>Clinical Immunology</i> , 2011 , 138, 239-46	9	23

131	Diversified serum IgG response involving non-myelin CNS proteins during experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2006 , 179, 53-64	3.5	23
130	Using mental visual imagery to improve autobiographical memory and episodic future thinking in relapsing-remitting multiple sclerosis patients: A randomised-controlled trial study. <i>Restorative Neurology and Neuroscience</i> , 2015 , 33, 621-38	2.8	22
129	Phrenic nerve palsy as a feature of chronic inflammatory demyelinating polyradiculoneuropathy. <i>Muscle and Nerve</i> , 2003 , 27, 497-9	3.4	22
128	Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 279-83	5.5	21
127	14-3-3 Protein in the cerebrospinal fluid of patients with acute transverse myelitis and multiple sclerosis. <i>Journal of Neurology</i> , 2002 , 249, 626-7	5.5	21
126	Paroxysmal kinesigenic choreoathetosis as a presenting symptom of multiple sclerosis. <i>Journal of Neurology</i> , 2000 , 247, 478-80	5.5	21
125	Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti-SARS-CoV-2 Antibodies: An Observational Study. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	21
124	Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study. <i>Journal of Neurology</i> , 2015 , 262, 1637-45	5.5	19
123	Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis. <i>CNS Drugs</i> , 2016 , 30, 41-51	6.7	19
122	Reduction of the washout time between natalizumab and fingolimod. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1248	5	19
121	Evaluation of clinical interest of anti-aquaporin-4 autoantibody followup in neuromyelitis optica. <i>Clinical and Developmental Immunology</i> , 2013 , 2013, 146219		19
120	Foreign accent syndrome as a first sign of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 1123-5	5	19
119	Pathologic laughing and intractable hiccups can occur early in multiple sclerosis. <i>Neurology</i> , 2006 , 67, 1684-6	6.5	19
118	Therapy related acute myeloblastic leukaemia after mitoxantrone treatment in a patient with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004 , 10, 92	5	19
117	Multiple sclerosis, interferon beta and clinical thyroid dysfunction. <i>Acta Neurologica Scandinavica</i> , 2003 , 107, 154-7	3.8	18
116	Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France		18
115	Tear analysis as a tool to detect oligoclonal bands in radiologically isolated syndrome. <i>Revue Neurologique</i> , 2015 , 171, 390-3	3	17
114	Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. <i>Journal of Neurology</i> , 2015 , 262, 326-36	5.5	16

113	Impaired mental simulation of specific past and future personal events in non-depressed multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 2014 , 345, 68-74	3.2	16
112	Extensive cerebral white matter involvement in a patient with NMO spectrum disorder. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1401-3	5	16
111	High-risk syndrome for neuromyelitis optica: a descriptive and comparative study. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 720-4	5	16
110	Double-blind crossover study with dolasetron mesilate, a 5-HT ₃ receptor antagonist in cerebellar syndrome secondary to multiple sclerosis. <i>Journal of Neurology</i> , 2003 , 250, 1190-4	5.5	16
109	Oligoclonal bands increase the specificity of MRI criteria to predict multiple sclerosis in children with radiologically isolated syndrome. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019 , 5, 2055217319836664	2	15
108	Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis. <i>PLoS ONE</i> , 2017 , 12, e0168834	3.7	15
107	Exploratory Phase II Trial to Evaluate the Safety and the Antiepileptic Effect of Pitolisant (BF2.649) in Refractory Partial Seizures, Given as Adjunctive Treatment During 3 Months. <i>Clinical Neuropharmacology</i> , 2016 , 39, 188-93	1.4	15
106	Multiple sclerosis and pregnancy. <i>Revue Neurologique</i> , 2014 , 170, 247-65	3	15
105	Robotic-assisted thymectomy with Da Vinci II versus sternotomy in the surgical treatment of non-thymomatous myasthenia gravis: early results. <i>Revue Neurologique</i> , 2013 , 169, 30-6	3	15
104	An autophagy-targeting peptide to treat chronic inflammatory demyelinating polyneuropathies. <i>Journal of Autoimmunity</i> , 2018 , 92, 114-125	15.5	14
103	Heroin inhalation-induced unilateral complete hippocampal stroke. <i>Neurocase</i> , 2013 , 19, 313-5	0.8	14
102	Effect of natalizumab on clinical and radiological disease activity in a French cohort of patients with relapsing-remitting multiple sclerosis. <i>Journal of Neurology</i> , 2012 , 259, 1215-21	5.5	14
101	Cognitive Dysfunction and Dementia in Primary Sjögren's Syndrome. <i>ISRN Neurology</i> , 2013 , 2013, 501327		14
100	Dalfampridine in hereditary spastic paraplegia: a prospective, open study. <i>Journal of Neurology</i> , 2015 , 262, 1285-8	5.5	13
99	Characterization of a new rat model for chronic inflammatory demyelinating polyneuropathies. <i>Journal of Neuroimmunology</i> , 2015 , 278, 1-10	3.5	13
98	Atypical forms of optic neuritis. <i>Revue Neurologique</i> , 2012 , 168, 697-701	3	13
97	Review of Animal Models of Neuromyelitis Optica. <i>Multiple Sclerosis and Related Disorders</i> , 2012 , 1, 174-179		13
96	OPA3-related autosomal dominant optic atrophy and cataract with ataxia and areflexia. <i>European Neurology</i> , 2012 , 68, 108-10	2.1	13

95	Brain MRI findings in long-standing and disabling multiple sclerosis in 84 patients. <i>Clinical Neurology and Neurosurgery</i> , 2010 , 112, 286-90	2	13
94	Mycophenolate mofetil and neurological diseases. <i>Lupus</i> , 2005 , 14 Suppl 1, s42-5	2.6	13
93	Sequential magnetic resonance imaging follow-up of multiple sclerosis before the clinical phase. <i>Multiple Sclerosis Journal</i> , 2005 , 11, 395-7	5	13
92	Inflammatory Optic Neuritis: From Multiple Sclerosis to Neuromyelitis Optica. <i>Neuro-Ophthalmology</i> , 2013 , 37, 141-145	0.9	12
91	Inflammatory-like presentation of CADASIL: a diagnostic challenge. <i>BMC Neurology</i> , 2012 , 12, 78	3.1	12
90	Methionine synthase deficiency: a rare cause of adult-onset leukoencephalopathy. <i>Neurology</i> , 2012 , 79, 386-8	6.5	12
89	Functional and structural cerebral changes in key brain regions after a facilitation programme for episodic future thought in relapsing-remitting multiple sclerosis patients. <i>Brain and Cognition</i> , 2016 , 105, 34-45	2.7	12
88	Neural correlates of episodic future thinking impairment in multiple sclerosis patients. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2015 , 37, 1107-23	2.1	11
87	Benefits from an autobiographical memory facilitation programme in relapsing-remitting multiple sclerosis patients: a clinical and neuroimaging study. <i>Neuropsychological Rehabilitation</i> , 2018 , 28, 1110-1130	3.1	11
86	PET follow-up in a case of anti-NMDAR encephalitis: arguments for cingulate limbic encephalitis. <i>Epileptic Disorders</i> , 2012 , 14, 90-3	1.9	11
85	Chronic inflammatory demyelinating polyradiculoneuropathy in solid organ transplant recipients: a prospective study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012 , 83, 699-705	5.5	11
84	Primary progressive multiple sclerosis: a comparative study of the diagnostic criteria. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 622-5	5	11
83	Serum-based differentiation between multiple sclerosis and amyotrophic lateral sclerosis by Random Forest classification of FTIR spectra. <i>Analyst, The</i> , 2019 , 144, 4647-4652	5	10
82	The Brown Norway opticospinal model of demyelination: does it mimic multiple sclerosis or neuromyelitis optica?. <i>International Journal of Developmental Neuroscience</i> , 2012 , 30, 487-97	2.7	10
81	Man-in-the-barrel syndrome caused by a pontine lesion. <i>Neurology</i> , 2005 , 64, 1703	6.5	10
80	Cardiac repolarization abnormalities in multiple sclerosis: spinal cord MRI correlates. <i>Muscle and Nerve</i> , 2000 , 23, 1284-6	3.4	10
79	Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017 , 4, e346	9.1	9
78	Novel SPG10 mutation associated with dysautonomia, spinal cord atrophy, and skin biopsy abnormality. <i>European Journal of Neurology</i> , 2013 , 20, 398-401	6	9

77	Assessing Autophagy in Sciatic Nerves of a Rat Model that Develops Inflammatory Autoimmune Peripheral Neuropathies. <i>Cells</i> , 2017 , 6,	7.9	9
76	Longitudinal change detection in diffusion MRI using multivariate statistical testing on tensors. <i>NeuroImage</i> , 2012 , 60, 2206-21	7.9	9
75	Serum IgG repertoire in clinically isolated syndrome predicts multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 593-600	5	9
74	A case of paraneoplastic demyelinating motor polyneuropathy. <i>Case Reports in Neurology</i> , 2012 , 4, 71-6	1	9
73	Interferon beta1a (Avonex) treatment in multiple sclerosis: similarity of effect on progression of disability in patients with mild and moderate disability. <i>Journal of Neurology</i> , 2002 , 249, 184-7	5.5	9
72	Atypical form of non-Langerhans histiocytosis with disseminated brain and leptomeningeal lesions. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000 , 69, 675-8	5.5	9
71	False positivity of anti aquaporin-4 antibodies in natalizumab-treated patients. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1231-4	5	9
70	Giving meaning to illness: An investigation of self-defining memories in patients with relapsing-remitting multiple sclerosis patients. <i>Consciousness and Cognition</i> , 2016 , 45, 200-209	2.6	9
69	FTY720 controls disease severity and attenuates sciatic nerve damage in chronic experimental autoimmune neuritis. <i>Journal of Neuroinflammation</i> , 2019 , 16, 54	10.1	8
68	Should a psychotic or manic episode be considered an early manifestation of Multiple Sclerosis? A multiple case study. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 6, 93-96	4	8
67	Evolution of self-reactive IgG antibody repertoires in patients with relapsing-remitting multiple sclerosis. <i>Immunology Letters</i> , 2005 , 97, 55-62	4.1	8
66	Resting-state functional MRI demonstrates brain network reorganization in neuromyelitis optica spectrum disorder (NMOSD). <i>PLoS ONE</i> , 2019 , 14, e0211465	3.7	7
65	Functional cerebral changes in multiple sclerosis patients during an autobiographical memory test. <i>Memory</i> , 2015 , 23, 1123-39	1.8	7
64	Immunological follow-up of patients with neuromyelitis optica: is there a good biomarker?. <i>Lupus</i> , 2013 , 22, 229-32	2.6	7
63	MOG-antibody neuromyelitis optica spectrum disorder: is it a separate disease?. <i>Brain</i> , 2017 , 140, 3072-3075	7	7
62	Recommendations for the detection and therapeutic management of cognitive impairment in multiple sclerosis. <i>Revue Neurologique</i> , 2012 , 168, 785-94	3	7
61	An a contrario approach for change detection in 3D multimodal images: application to multiple sclerosis in MRI. <i>Annual International Conference of the IEEE Engineering in Medicine and Biology Society</i> , 2007 , 2007, 2069-72		7
60	Recommendations for useful serum testing with suspected multiple sclerosis. <i>Revue Neurologique</i> , 2013 , 169, 37-46	3	6

59	Severe and rapidly evolving peripheral neuropathy revealing sporadic Creutzfeldt-Jakob disease. <i>Journal of Neurology</i> , 2009 , 256, 134-6	5.5	6
58	Mechanism of action of s1p receptor modulators in multiple sclerosis: The double requirement. <i>Revue Neurologique</i> , 2020 , 176, 100-112	3	6
57	Emotional disturbances in multiple sclerosis: A neuropsychological and fMRI study. <i>Cortex</i> , 2019 , 117, 205-216	3.8	6
56	Pathologic and MRI analysis in acute atypical inflammatory demyelinating lesions. <i>Journal of Neurology</i> , 2019 , 266, 1743-1755	5.5	5
55	Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO). <i>BMJ Open</i> , 2020 , 10, e035397	3	5
54	Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies. <i>Journal of Neuroinflammation</i> , 2020 , 17, 128	10.1	5
53	Isolated anti- α -glycoprotein I antibodies in neurology: a frontier syndrome between multiple sclerosis and antiphospholipid syndrome?. <i>European Journal of Neurology</i> , 2014 , 21, 901-6	6	5
52	The diagnosis of chronic inflammatory demyelinating polyneuropathy: a Delphi-method approach. <i>Journal of Neurology</i> , 2013 , 260, 3015-22	5.5	5
51	Evaluation of new immunological targets in neuromyelitis optica. <i>Journal of Peptide Science</i> , 2013 , 19, 25-32	2.1	5
50	Longitudinal change detection: inference on the diffusion tensor along white matter pathways. <i>Medical Image Analysis</i> , 2013 , 17, 375-86	15.4	5
49	Evaluation of an albumin-binding gadolinium contrast agent in multiple sclerosis. <i>Neurology</i> , 2013 , 81, 206-10	6.5	5
48	Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder. <i>Current Opinion in Neurology</i> , 2019 , 32, 111-114	7.1	5
47	Retinal Optical Coherence Tomography in Neuromyelitis Optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	5
46	Anti-pseudo-PCNA type 1 (anti-SG2NA) pattern: Track down Cancer, not SLE. <i>Joint Bone Spine</i> , 2016 , 83, 330-4	2.9	4
45	A case of recurrent facial pain associated with a Pourfour du Petit syndrome: a new entity?. <i>Headache</i> , 2014 , 54, 373-7	4.2	4
44	Recommendations for the management of multiple sclerosis relapses. <i>Revue Neurologique</i> , 2012 , 168, 425-33	3	4
43	An a contrario approach for outliers segmentation: Application to Multiple Sclerosis in MRI 2008 ,		4
42	Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay. <i>Clinica Chimica Acta</i> , 2008 , 391, 98-101	6.2	4

41	Molecular analysis of endogenous retrovirus HRES-1: identification of frameshift mutations in region encoding putative 28-kDa autoantigen. <i>Biochemical and Biophysical Research Communications</i> , 2001 , 283, 437-44	3.4	4
40	Multiple sclerosis with atypical MRI presentation: Results of a nationwide multicenter study in 57 consecutive cases. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 28, 109-116	4	4
39	Pregnancy in Patients With AQP4-Ab, MOG-Ab, or Double-Negative Neuromyelitis Optica Disorder. <i>Neurology</i> , 2021 , 96, e2006-e2015	6.5	4
38	Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.. <i>Lancet Neurology, The</i> , 2022 ,	24.1	4
37	Biotherapy in Inflammatory Diseases of the CNS: Current Knowledge and Applications. <i>Current Treatment Options in Neurology</i> , 2017 , 19, 19	4.4	3
36	Asthma as a cause of persistent dyspnea in treated myasthenia gravis patients. <i>European Neurology</i> , 2012 , 68, 300-3	2.1	3
35	Novel advances in the diagnosis and treatment of neuromyelitis optica: is there a need to redefine the gold standard?. <i>Expert Review of Clinical Immunology</i> , 2013 , 9, 979-86	5.1	3
34	Case 173: acute disseminated encephalomyelitis confined to the brainstem. <i>Radiology</i> , 2011 , 260, 911-4	20.5	3
33	Obstructive sleep apnoea: an underestimated cause of peripheral neuropathy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 222	5.5	3
32	Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome. <i>JAMA Network Open</i> , 2021 , 4, e2128271	10.4	3
31	Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 729-741	5	3
30	Aquaporin 4 distribution in the brain and its relevance for the radiological appearance of neuromyelitis optica spectrum disease. <i>Journal of Neuroradiology</i> , 2021 , 48, 170-175	3.1	3
29	How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP). <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 53, 103076	4	3
28	Distinct and common cerebral activation changes during mental time travel in relapsing-remitting multiple sclerosis patients. <i>Brain Imaging and Behavior</i> , 2016 , 10, 296-313	4.1	2
27	Chronic Bickerstaff's encephalitis with cognitive impairment, a reality?. <i>BMC Neurology</i> , 2014 , 14, 99	3.1	2
26	Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis. <i>BMC Neurology</i> , 2014 , 14, 215	3.1	2
25	Recommendations for a definition of multiple sclerosis in support of early treatment. <i>Revue Neurologique</i> , 2012 , 168, 328-37	3	2
24	Interferon beta in multiple sclerosis: relationship between sustained serum IgG levels and clinical outcome. <i>Journal of Neuroimmunology</i> , 2002 , 129, 232	3.5	2

23	BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1556-1563	5	2
22	Asian and African/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residence. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 53, 103080	4	2
21	Targeted clinical audits immediately following the establishment of clinical practice guidelines for multiple sclerosis in 17 neurology departments: A pragmatic and collaborative study. <i>Revue Neurologique</i> , 2015 , 171, 407-14	3	1
20	Thérapeutiques et prise en charge de la sclérose en plaques 2017 , 145-216		1
19	Multiple sclerosis with normal neuro-ophthalmological work-up: results of focal stimulations induced by a scanning laser ophthalmoscope. <i>Acta Neurologica Scandinavica</i> , 2000 , 101, 311-4	3.8	1
18	Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study.. <i>Journal of Neurology</i> , 2022 , 1	5.5	1
17	Good therapeutic response to infliximab in a case of Susac syndrome refractory to immunotherapies including tocilizumab.. <i>Journal of Neurology</i> , 2022 , 1	5.5	1
16	Longitudinal change detection: inference on the diffusion tensor along white-matter pathways. <i>Lecture Notes in Computer Science</i> , 2011 , 14, 1-8	0.9	1
15	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. <i>CNS Drugs</i> , 2021 , 35, 1217-1232	6.7	1
14	MSCopilot: New smartphone-based digital biomarkers correlate with Expanded Disability Status Scale scores in people with Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 55, 103164	4	1
13	CIDP: Current Treatments and Identification of Targets for Future Specific Therapeutic Intervention. <i>Immuno</i> , 2022 , 2, 118-131		0
12	Emotional experience is increased and emotion recognition decreased in multiple sclerosis. <i>Scientific Reports</i> , 2021 , 11, 21885	4.9	0
11	Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod Withdrawal.. <i>Neurotherapeutics</i> , 2022 , 1	6.4	0
10	Diagnostics différentiels de la sclérose en plaques 2017 , 113-143		
9	Signes et symptômes de la sclérose en plaques 2017 , 3-78		
8	No evidence for genetic association between glutamate transporter EAAT2 and DevicB neuromyelitis optica in caucasians and afro-caribbeans. <i>Multiple Sclerosis and Related Disorders</i> , 2014 , 3, 89-93	4	
7	Prise en charge thérapeutique des manifestations neuropsychiatriques du lupus érythémateux 2013 , 265-271		
6	Monophasic Acute, Recurrent, and Multiphasic Disseminated Encephalomyelitis and Multiple SclerosisReply. <i>Archives of Neurology</i> , 2008 , 65, 672		

- 5 Differential Diagnosis Between Acute Disseminated Encephalomyelitis and Multiple Sclerosis During the First Episode Reply. *Archives of Neurology*, **2008**, 65, 672
- 4 Multiple Sclerosis and Recurrent Disseminated Encephalomyelitis Are Different Diseases Reply. *Archives of Neurology*, **2008**, 65, 672
- 3 Overview of treatment of NMO. *Acta Ophthalmologica*, **2014**, 92, 0-0 3·7
- 2 Antibodies, MRI and unusual clinical features of NMO. *Acta Ophthalmologica*, **2014**, 92, 0-0 3·7
- 1 Diagnostic positif de la sclérose en plaques **2017**, 79-111